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Background: Acute exacerbations are important in the clinical course of COPD, yet the
underlying mechanisms are poorly understood. Systemic inflammation is now considered as
an important component in the disease process. In this study we evaluated longitudinally
the systemic inflammation during hospital treatment for acute exacerbation and after
clinical recovery.
Methods: Blood was collected on day 0, 1, 4 and 8 in 21 patients admitted for an acute
exacerbation of COPD and at 1 month, 3 months and 6 months after discharge. Systemic
inflammation was determined by measurement of the pro-inflammatory markers
interleukin (IL)-6, soluble tumor necrosis factor (TNF) receptors sTNFR55 and sTNFR75,
the anti-inflammatory mediator sIL-1RII, and bactericidal permeability increasing protein
(BPI) as a marker of neutrophil activation. In addition, plasma level of Trolox antioxidant
capacity (TEAC) was determined. Healthy age-matched controls were measured for the
same markers at one time-point.
Results: All inflammatory markers analyzed were elevated on first day of admission for
exacerbation of COPD, as compared to healthy controls. During treatment, levels of IL-6,
and sTNFR75 rapidly decreased, whereas sTNFR55 and BPI remained elevated. Moreover,
sIL-1RII and TEAC increased during first 8 days of treatment. In the stable condition all
inflammatory markers returned to values comparable to healthy controls, with the
exception of BPI, which remained persistently elevated compared to healthy controls.Elsevier Ltd. All rights reserved.
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K.H. Groenewegen et al.2410Conclusion: This study clearly demonstrates upregulation of systemic inflammation in
acute exacerbations of COPD. Attenuation of systemic inflammation may offer new
perspectives in the management of COPD patients to reduce the burden of exacerbations.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality throughout the world.
Hospital admission for acute exacerbations forms the major
component of the economical burden of COPD in western
countries.1 Generally, acute exacerbations are character-
ized by varying combinations of symptoms as increase in
cough, sputum production, worsening of dyspnea or changes
in sputum purulence. Despite the important role of these
acute exacerbations in the clinical course of COPD, under-
lying pathogenic mechanisms are poorly understood.
Inflammation is a prominent feature of COPD as shown by
the presence in the airways of activated neutrophils and
macrophages and increased numbers of inflammatory
mediators.2,3 Exacerbations of COPD are generally consid-
ered to reflect a flare-up of these underlying inflammatory
processes, although information about the inflammatory
response in the lungs, particularly during severe exacerba-
tions, is still limited. Recent studies showed increased
airway inflammation during exacerbations, as measured by
increased sputum neutrophil, eosinophil and lymphocyte
counts, increased sputum myeloperoxidase (MPO) and IL-8,
and activation of NF-kappa B in sputum macrophages,
compared to the stable phase.4–7
Besides the abnormal local inflammatory response,
systemic inflammation is now considered an important
component in the disease process. This systemic inflamma-
tion is related to the systemic consequences of COPD,
including involuntary weight loss, muscle dysfunction and
wasting, and increased cardiovascular morbidity.8 Increased
systemic inflammation during acute exacerbations of COPD
is indicated by increased levels of the acute phase proteins
C-reactive protein (CRP) and fibrinogen, elevated levels of
cytokines as IL-6, and the neutrophil marker MPO.9–11 In
addition, the anti-inflammatory mediator sIL-1RII was shown
to increase progressively during treatment of exacerba-
tion.12 Recently, Hurst et al. published an extensive
evaluation of a panel of potential biomarkers at exacerba-
tion, from which CRP was the most selective biomarker.13
Moreover, a decreased plasma anti-oxidant capacity was
observed during exacerbations.14
Most of the presently available data are obtained in cross-
sectional studies not taking into account the time to
recovery to the baseline stable state. The aim of our study
was to evaluate longitudinally the course of a panel of
systemic inflammatory mediators, and the anti-oxidant
capacity, during hospital treatment for acute exacerbation
and after clinical recovery, in patients with severe COPD. As
a control group healthy age-matched control subjects
were analyzed. Our hypothesis was a demonstration of a
differential time response pattern of a panel of inflamma-
tory mediators as well as of anti-oxidative capacity during
and in the recovery phase of acute exacerbations andassessment of COPD related disease markers in the stable
disease condition.Materials and methods
Study population
Patients with acute exacerbation: The study population
consisted of 21 patients consecutively admitted to the
University Hospital Maastricht for an acute exacerbation of
COPD. COPD was defined as forced expiratory volume in 1
second (FEV1)o80% predicted for age and height, b2 agonist
reversibility ofo11% of predicted and airflow obstruction
evidenced by a ratio of FEV1 to forced vital capacity (FVC) of
o0.70 of predicted according to ATS criteria.15 Patients
with important co-morbid conditions as malignancies,
diabetes mellitus, thyroid and cardiovascular diseases, were
excluded from the study in order to avoid non-COPD related
interfering factors. Patients, already treated with antibio-
tics and/or corticosteroid therapy on admission, were also
excluded from the study. Furthermore, if patients had a
recurrent exacerbation within the follow-up period of 6
months, they were excluded from the study.
The presence of an acute exacerbation was defined as the
presence of one or more the following symptoms: (1)
increased cough and sputum volume, (2) increased sputum
purulence, and (3) increased dyspnea. All 21 patients were
classified as a type 1 exacerbation, based on the Anthonisen
criteria.16 Patients were treated according to a standard
protocol with nebulized salbutamol and ipratropiumbro-
mide, intravenous prednisolone in a dosage of 0.5mg/kg.
Duration of intravenous therapy was 4 days. On day 4
patients were switched to an oral tapering schedule of
prednisolone. Specific antibiotic treatment was adminis-
tered to patients in case of positive sputum cultures. A
sputum culture was considered as positive (proving bacterial
infection) if significant bacterial growth was present as
defined by the number of bacteria (higher than 105 colony
forming units ¼ cfu) in a representative sample. Antibiotic
treatment was based on resistance assessment of identified
bacteria. Patients were evaluated for inflammatory markers
on day 0 (admission) before the start of treatment, day 1,
day 4 and day 8 of hospitalization for acute exacerbation.
Patients were discharged based on clinical judgment of an
experienced, independent chest physician.
After discharge, patients were evaluated after 1 month, 3
months and 6 months. The study was approved by the
medical ethical committee of the University Hospital
Maastricht and all participants have given their written
informed consent.
Healthy controls: The healthy control group consisted of
20 subjects who were age and gender matched and without
any evidence of COPD based on questionnaires and lung
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chronic diseases, based on analysis of the clinical history and
medical examination. Control subjects were living in the
same area as the patients. Control subjects were evaluated
for inflammatory markers at 1 time-point. Control subjects
without manifested morbid conditions were chosen to find
out COPD-related changes in systemic mediators during the
recovery period and after the supervised 6-month period
when the disease was considered stable.
Lung function measurements: On admission for an acute
exacerbation, arterial blood gases at rest were assessed by
puncture of the radial artery during room air breathing. On
days 1, 4 and 8 of admission and 1, 3 and 6 months after
discharge, forced expiratory volume in one second (FEV1)
and inspiratory vital capacity (IVC) were calculated from the
flow-volume curve, using a portable pneumotachograph
(Jaeger instruments, Wu¨rzburg, Germany). Flow–volume
curves were performed at a standardized time point, one
hour after medication. Lung function values were expressed
as a percentage of the reference values.
Measurement of inflammatory parameters and TEAC in
plasma: Blood was collected in EDTA containing tubes.
(Sherwood Medical, St. Louis, MO, US) The blood samples
were put on ice immediately and kept on ice during the
entire preparation. Plasma was separated by centrifugation
at 167 g for 10min at 4 1C and two aliquots were centrifuged
at 3000 rpm. Supernatants were collected and stored at
70 1C until analysis for cytokines and anti-oxidants.
Inflammatory mediators were measured in plasma by
sandwich enzyme-linked immunosorbent assay (ELISA), as
described previously.12 Briefly, for detection of sTNF-R55
and sTNF-R75, monoclonal antibodies MR1-1 and MR2-2 were
used for coating and specific biotin labeled polyclonal rabbit
anti-human (h)-sTNF-R IgG as detector reagents. For sIL-1RII
measurements, plates were coated with monoclonal anti-
body 8.5 against shIL-1RII and detection was carried out with
a biotinylated polyclonal rabbit anti-shIL-1RII IgG. For IL-6
and BPI measurements, plates were coated with murine
monoclonal antibody 5E1 and human BPI specific monoclonal
antibody 4E3, respectively. Biotinylated polyclonal rabbit
anti-human IL-6 antiserum and biotinylated polyclonal
rabbit anti-human BPI IgG were used as detection anti-
bodies. All plasma samples were measured in the same run.Table 1 Characteristics of COPD patients with acute exacerba
Patients (n ¼ 21)
Age (yr) 66.779.0
Sex F/M 6/15
BMI (kg/m2) 23.574.7
FEV1% pred 35.0714.4
IVC % pred 62.9722.9
Smokers current/ex/none 7/13/1
Pack-years 40720
Inhaled steroids Y/N 19/2
Bacterial infection Y/N 12/9
PaO2 (mmHg) 53.2710.5
PaCO2 (mmHg) 47.2716.5
Values of patients are values on admission. Data are presented as mFor analysis of TEAC, plasma was deproteinized. An
aliquot of 150 ml of plasma was deproteinized by mixing
with an equal volume of 10% (w/v) TCA, and after
centrifugation for 5min at 14,000 rpm the supernatant was
used for spectrophotometrical analysis. TEAC was deter-
mined enzymatically (Sigma) as described by Van den Berg
et al.17
Statistics: Differences in parameters within an individual
patient between two time points were compared using
Wilcoxon matched pairs signed rank test. Because we have
performed planned comparisons in a relatively small sample
size, no multiple comparisons tests were performed.18
Differences between patients and controls were measured
using the Mann–Whitney U-test. Significance was deter-
mined at the 5% level. Data were analyzed using the SPSS for
Windows statistical package (version 12.0, SPSS Inc.,
Chicago, IL, US). Data were expressed as mean (7SD).Results
Clinical parameters: The characteristics of the COPD
patients on admission for an acute exacerbation and healthy
controls are summarized in Table 1. On average, the
duration of admission was 9.4 days (range 5–14). There
was a small improvement in FEV1 during the clinical course
of acute exacerbation, which was not statistically significant
(from 0.9070.03 l on admission to 0.9770.04 l on day 8;
p ¼ 0.19). There was a significant improvement in PaO2
during admission (from 53.9710.2mmHg on admission to
64.778.7mmHg on day 8; p ¼ 0.001). PaCO2 values did not
change significantly (data not shown).
Twelve of 21 patients had a positive sputum culture, 9
patients with 1 microorganism and 3 patients with 2
microorganisms. Microorganisms cultured were Streptococ-
cus pneumoniae (6 patients), Haemophilus influenzae
(8 patients), and Moraxella catharralis (1 patient). No
differences existed in any of the measured parameters
between patients with and without positive sputum
cultures.
Inflammatory markers: Fig. 1 shows the time course of
the inflammatory mediators on day 0, 1, 4 and 8 during
admission for an acute exacerbation of COPD and at 1tion and healthy controls
Controls (n ¼ 20) p-Value
60.673.4 NS
6/14 NS
25.972.7 NS
108.2714.2 0.0001
114.8712.4 0.0001
1/11/8 NS
20715 0.0001
0/20 0.0001
NA
NA
NA
ean 7 SD.
ARTICLE IN PRESS
L
e
v
e
l 
o
f 
IL
-6
 (
n
g
/m
l)
∗
# #
#
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
L
e
v
e
l 
o
f 
s
T
N
F
R
7
5
 (
n
g
/m
l
∗
#
#
0
0.5
1
1.5
2
2.5
3
L
e
v
e
l 
o
f 
s
T
N
F
R
 5
5
 (
n
g
/m
l)
0
0.5
1
1.5
2
2.5
L
e
v
e
l 
o
f 
s
 I
L
1
 R
II
 (
n
g
/m
l)
∗
∗
∗ ∗
0
1
2
3
4
5
6
7
8
9
10
day 1 day 4 day 8 1 month 3 months 6 monthsday 0 day 1 day 4 day 8 1 month 3 months 6 months
day 0 day 1 day 4 day 8 1 month 3 months 6 months day 0 day 1 day 4 day 8 1 month 3 months 6 months
day 0
∗ ∗
∗
L
e
v
e
l 
o
f 
B
P
I 
(n
g
/m
l)
∗
∗ #
∗ #
∗
∗
∗
∗
0
0.5
1
1.5
2
2.5
3
3.5
4
day 0 day 1 day 4 day 8 1 month 3 months 6 months
Fig. 1 Course of inflammatory mediators (A. IL-6, B. sTNFR75, C. sTNFR55, D. sIL-1RII, E. BPI) during and after acute exacerbation
of COPD. Data shown are means7SD. Dots represent patient data; open squares represents values from healthy controls. : po0.05
versus healthy controls. ]: po0.05 versus value on day 0.
K.H. Groenewegen et al.2412month, 3 months and 6 months after discharge. As
comparison, levels were also measured in healthy controls.
The cytokine IL-6 was not detectable in the healthy control
subjects with the assay used, therefore, detection limit of
the assay (20 pg/ml) was indicated in the figure. On the day
of admission, IL-6 was significantly enhanced in patients as
compared to healthy controls (p ¼ 0.033). After one day of
treatment levels dropped strongly (day 0 to day 1:
p ¼ 0.043) and were no longer different from control
subjects. Surprisingly, enhanced levels of IL-6 were seen 1
month after discharge, however, this enhancement was not
significant. Likewise, the sTNFR75 was enhanced at admis-
sion of exacerbation, and declined thereafter (day 0–day 1:
p ¼ 0.01; day 1–day 4: p ¼ 0.019). After 1 month ofdischarge, increased levels of sTNFR75 were observed
(day 8 to month 1: p ¼ 0.028), and declined thereafter
(month 1–month 6: p ¼ 0.013). Soluble TNFR55 was ele-
vated during all time points of acute exacerbation of COPD,
with exception of the day 4 time point (day 1–day 4:
p ¼ 0.004). After 1, 3 and 6 months, levels were no longer
different as compared to healthy controls. The anti-
inflammatory marker sIL-1RII was significantly increased on
the day of admission and increased further during treatment
of exacerbation (day 0–day 1: p ¼ 0.031; day 1–day 4:
p ¼ 0.038). In the recovery period sIL-1RII decreased to
levels comparable to healthy controls (day 8 to 1 month;
p ¼ 0.004). Also the neutrophil marker BPI was elevated on
admission (p ¼ 0.0001), and remained elevated during and
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Longitudinal follow-up of systemic inflammation 2413after recovery of exacerbation, as compared to control
subjects. Highest BPI levels were seen on day 8 and lowest at
3 months after exacerbation (day 8 to month 3: p ¼ 0.01).
Anti-oxidant capacity: The change in levels of systemic
anti-oxidant TEAC during treatment of acute exacerbation
and after recovery is shown in Fig. 2. There was a significant
increase in TEAC levels during treatment of acute exacer-
bation, compared to admission values (day 0–day 8:
p ¼ 0.003). After discharge, levels decreased significantly
(month 3–month 6: p ¼ 0.017).Discussion
This study showed elevated levels of systemic inflammatory
markers IL-6, sTNFR55, sTNFR75, and sIL-1RII as well as
neutrophil protein BPI, on admission for acute exacerbation
of COPD. During treatment, there was a rapid decrease in
IL-6, and sTNFR75, whereas in contrast sTNFR55 and BPI
remained elevated. Moreover, sIL-1RII and TEAC increased
during first 8 days of treatment. In the stable condition,
inflammatory markers returned to values comparable to
healthy controls, with the exception of BPI, which remained
persistently elevated compared to healthy controls.
Growing evidence exists about the upregulation of
systemic inflammation, as manifested by an elevated acute
phase response, as part of the underlying pathogenetic
processes ongoing during acute exacerbations.19 In this
study, elevated levels of IL-6 were found on admission for an
acute exacerbation, compared to healthy controls. During
recovery and follow-up, IL-6 is in the same range as in
healthy controls, suggesting a short flare-up of systemic
inflammation at the beginning of the exacerbation. IL-6 is
the most important cytokine in the hepatic synthesis of
acute phase proteins. Moreover, IL-6 is important in
regulating levels of fibrinogen, the precursor to fibrin in
the coagulation cascade. Elevated fibrinogen levels and IL-6
are associated with increased cardiovascular mortality and
morbidity.20,21 It has already been demonstrated that during
acute exacerbation levels of fibrinogen and IL-6 rise
further.22 In this way, increased systemic inflammation can
predispose to cardiovascular events.TNFa is a pro-inflammatory cytokine, which has been
found in increased levels in airways and circulation of COPD
patients.23–25 TNFa mediates intracellular signaling via two
receptors: a 55 kDa receptor (TNFR55) and a 75 kDa receptor
(TNFR75). A variety of inflammatory stimuli, including
endogenous TNFa formation, is known to induce proteolytic
shedding of the extracellular cytokine-binding domains of
the TNF receptors.26 Therefore soluble TNF receptors are
considered as pro-inflammatory markers. Earlier studies of
our group have shown an increase in soluble TNF receptors
during treatment of acute exacerbation.27 In this study we
found that on admission for acute exacerbation, before the
start of treatment, levels of both sTNF-receptors were
elevated. During treatment sTNFR75 levels rapidly de-
creased whereas sTNFR55 remained elevated. One, 3 and
6 months after acute exacerbation, levels of both TNF
receptors were not different from healthy controls.
Besides monitoring of the changes in inflammatory
mediators to predict diagnosis, outcome and prognosis of
acute exacerbations, further studies are needed to inte-
grate these findings in order to better understand ongoing
processes during exacerbations of COPD. Acute phase
responses are involved in activation of the classical
complement pathway.28 Biochemical markers as CRP, IL-6
and TNF-a are generally considered as biochemical markers
of endothelial dysfunction; particularly CRP represents one
of the strongest independent predictors of vascular morbid-
ity and mortality.29,30 The role of systemic inflammation to
shift the hemostatic balance in favor of the activation of
coagulation during acute exacerbations of COPD remains
largely unexplored.31
IL-1 is a pro-inflammatory cytokine, and has two
receptors: type I receptor which mediates cellular activa-
tion and type II receptor which acts as a decoy receptor.12
Both IL-1 receptors are present in soluble forms and the
soluble receptors inactivate sIL-1. In patients with stable
COPD normal levels of sIL-1RII have been found, which
increase during treatment of acute exacerbations, indicat-
ing that an upregulation of anti-inflammatory cytokines is
present during treatment of COPD exacerbations.12 In this
study we have confirmed and expanded those findings. We
found elevated levels of sIL-1 RII on admission for acute
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increased further during treatment. This supports the
hypothesis that recovery of acute exacerbations is asso-
ciated with an increase in anti-inflammatory capacity. After
a follow-up period of 1, 3 and 6 months, sIL-1RII levels are
comparable to healthy controls. Future studies should
include the course of other anti-inflammatory mediators
such as IL-10 in the course of acute exacerbation. Modula-
tion of anti-inflammatory effects can contribute to fasten
the recovery after acute exacerbations.
BPI is stored within the azurophilic granules of neutrophils
and can be released upon direct stimulation of the
neutrophil by bacterial endotoxins, but also by inflammatory
stimuli like TNF-a.32 Therefore it can be used as a marker for
neutrophilic activation. So far no data exist on BPI levels in
COPD patients. We demonstrated increased systemic levels
of BPI in COPD patients with an acute exacerbation in
comparison to healthy control subjects. These data suggest
ongoing neutrophilic activation in COPD patients, in clini-
cally stable patients and during acute exacerbations. This is
in line with other reports indicating that recruitment and
activation of neutrophils is an important event in the
pathogenesis of COPD.3,33 Elevated levels of serum MPO
and serum ECP have been found during exacerbations
indicating neutrophilic and eosinophilic activation.9 Noguera
et al. reported that circulating neutrophils from COPD
patients produced more reactive oxygen species and the
level of expression of several surface adhesion molecules in
circulating neutrophils is higher in stable COPD patients
than in healthy controls. Interestingly, this difference
disappeared during acute exacerbations, suggesting neutro-
phil sequestration in the pulmonary circulation.34 A recent
study found activated neutrophils in the circulation of stable
COPD patients, which correlated with disease severity.35
The question is whether and to what extent the course of
inflammatory parameters was influenced by the anti-
inflammatory treatment our patients received. Corticoster-
oids are potent immunosuppressive agents that are known to
affect T-cell mediated inflammation by the inhibition of
proliferation and cytokine production, as well as the
immuno-stimulatory function of monocytes and macro-
phages.36 Moreover, in vitro experiments have shown that
exposure of cells to the steroid analogue dexamethasone
resulted in enhanced membrane expression of IL-1RII
followed by augmented release of the receptor over a
period of 18–24 h.37 Treatment with systemic steroids thus
may be partially responsible for the course of systemic
inflammatory mediators that we have observed after
admission. In line herewith, studies in cardiac surgery
patients have shown a decrease in circulating levels of
TNF and IL-6 after treatment with corticosteroids.38,39 Since
our patients did not receive corticosteroids before admis-
sion, the enhanced levels of inflammatory parameters
observed on day 0 cannot be attributed to treatment
effects. Steroid treatment of patients was, according to a
standard schedule, tapered after 4 days during a period of
15 days. Interpretation of the course of systemic inflamma-
tory parameters in the recovery period is therefore also
most likely not influenced by steroid therapy.
A number of studies have demonstrated an increased
oxidative stress in COPD patients, especially during exacer-
bations.14,40,41 Our study demonstrates an increase in totalanti-oxidant capacity during treatment of acute exacerba-
tion, suggesting that improvement in antioxidant capacity
may be a contributing factor in recovery from acute
exacerbations.
These results were found in a group of patients with
severe COPD, admitted for an acute exacerbation, which
remained stable during 6 months of follow-up. We realize
this is probably a selected population, since patients with
exacerbations in the follow-up period and patients with
cardiovascular co-morbidity were excluded. Therefore these
results are probably not generally applicable in all popula-
tions of COPD patients. Otherwise, our results after the
6-month follow-up period clearly illustrate the importance
of careful assessment and monitoring of the clinical condition
in the evaluation of inflammatory systemic mediators. This
is particularly important when systemic inflammation will be
evaluated as part of the phenotyping of COPD.
In conclusion, this study clearly demonstrated upregula-
tion of systemic inflammation in acute exacerbations of
COPD. During recovery pro-inflammatory markers declined
whereas levels of sIL-1RII and TEAC increased. In the stable,
state inflammatory markers were no longer enhanced with
the exception of neutrophil marker BPI. Attenuation of
systemic inflammation may offer new perspectives in the
management of COPD patients to reduce the burden of
exacerbations.References
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